Sign up to save your podcasts
Or
Share The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering: OCEAN(a)-DOSE Extension Period Results
In this episode, Dr. Valentin Fuster explores findings from the Phase 2 OCEAN-LDO trial assessing the off-treatment effects of the RNA-based drug alpcisiran on lipoprotein(a) [Lp(a)] levels. The study found that high doses of alpcisiran reduced Lp(a) levels by up to 95% during treatment, with a sustained reduction of 27-76% persisting up to 96 weeks after discontinuation, and no new safety concerns emerged.
View all episodes
By American College of Cardiology
4.2
154154 ratings
In this episode, Dr. Valentin Fuster explores findings from the Phase 2 OCEAN-LDO trial assessing the off-treatment effects of the RNA-based drug alpcisiran on lipoprotein(a) [Lp(a)] levels. The study found that high doses of alpcisiran reduced Lp(a) levels by up to 95% during treatment, with a sustained reduction of 27-76% persisting up to 96 weeks after discontinuation, and no new safety concerns emerged.
More shows like JACC This Week
View all
JAMA Editors' Summary
131 Listeners
NEJM This Week
325 Listeners
This Week in Cardiology
865 Listeners
JAMA Clinical Reviews
496 Listeners
JACC Specialty Journals
22 Listeners
Circulation on the Run
31 Listeners
The Curbsiders Internal Medicine Podcast
3,336 Listeners
JAMA Medical News
90 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
138 Listeners
Core IM | Internal Medicine Podcast
1,095 Listeners
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
61 Listeners
ACC CardiaCast
39 Listeners
Annals On Call Podcast
185 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
Cardionerds: A Cardiology Podcast
427 Listeners